PSA response


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

PSA response

A decrease in the level of prostate-specific antigen (PSA) of at least 50% in a patient receiving treatment for prostate cancer.
See also: response
References in periodicals archive ?
6: TROPIC data on objective tumor response (in patients with measurable disease, n=405), PSA response (in evaluable patients, n=654) and pain response (evaluated in patients with high scores for pain and/or analgesia use, n=342).
In patients treated with luteinizing-hormone-releasing hormone agonist monotherapy or who have had an orchidectomy, total androgen blockade (TAB) with testosterone antagonists, such as bicalutamide, can offer PSA responses in 30% to 35% of patients.
Overall survival was also analyzed after stratifying patients by PSA response (50% decline from baseline) and by PSAHL at 42 days postdocetaxel and at 84 days post-docetaxel initiation.
PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint.
PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.
Results presented at the Symposium showed a PSA response of at least 50 percent in 78 percent of the 27 evaluable patients and also showed that the combination of picoplatin and full-dose docetaxel can be safely administered.
The secondary objectives were to determine the efficacy of OGX-011 in combination with second-line chemotherapy in terms of PSA response, pain progression and survival as well as exploring the relationship between serum clusterin levels with those parameters.
Two patients requiring thyroid replacement therapy were successfully tapered off after recovery of thyroid function, with one patient subsequently maintaining a PSA response.
Of the 29 efficacy evaluable patients, one patient with anaplastic thyroid carcinoma had a partial response, one patient with hormone refractory prostate cancer demonstrated a confirmed partial PSA response, and 18 patients had disease stabilization.